Analysis of Metabolic Characteristics of Epristeride in Zebrafish Based on LC-Q-TOF MS and Its Potential Applications in Doping Control

This review discusses the current therapies for androgenic alopecia, emphasizing topical formulations like minoxidil and finasteride and exploring the potential of dutasteride-loaded nanocarriers for targeting hair follicles to minimize systemic side effects from oral treatment.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This study found that the metabolic profile of finasteride in pigs closely matches that of humans, supporting the use of pigs for studying human drug metabolism.

This study identified previously unknown phase I and phase II metabolites of finasteride in human bile and urine using a specialized bile collection technique and advanced mass spectrometry analysis.